<?xml version="1.0" encoding="UTF-8"?>
<TemplateContainer creationDate="2014-03-26" authors="ATS 1.1" name="ATS Template" version="1" uid="2.25.170949739334841098337550023224864544330" description="Template container generated by ATS 1.1" xsi:schemaLocation="gme://caCORE.caCORE/3.2/edu.northwestern.radiology.AIMTemplate AIMTemplate_v2rv13.xsd" xmlns="gme://caCORE.caCORE/3.2/edu.northwestern.radiology.AIMTemplate" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<Template templateType="Image" xmlns="gme://caCORE.caCORE/3.2/edu.northwestern.radiology.AIMTemplate" uid="2.25.78144447119639723322342387224335529350" name="VASARI 4.1-1" authors="Justin Kirby" version="4.1" creationDate="2013-08-26" description="Baseline Glioma MR tumor assessment to include potential features for low grade glioma (LGG)." modality="MR" codeMeaning="VASARI" codingSchemeDesignator="99PRI_TempCode-1" codeValue="99PRI_TC_0A23-5-1" codingSchemeVersion="1.0">
      <Component label="Tumor" itemNumber="0" authors="Justin Kirby" explanatoryText="" minCardinality="1" maxCardinality="1" shouldDisplay="false" groupLabel="" id="2.25.150776022310855362644669615058239870060">
         <ImagingObservation annotatorConfidence="false">
            <ImagingObservationCharacteristic label="F0 - Image QA" itemNumber="0" authors="Justin Kirby" explanatoryText="Quality assurance pre-check. Inventory of required image series including FLAIR/T2 and pre/post contrast T1WI." minCardinality="0" maxCardinality="4" shouldDisplay="true" groupLabel="" id="2.25.41762360117754513539982904068277651900" annotatorConfidence="false">
               <AllowedTerm codeValue="01" codeMeaning="Post biopsy (requires adjudication)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="02" codeMeaning="Post-op study (disqualified)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" noMoreQuestions="true"/>
               <AllowedTerm codeValue="03" codeMeaning="No Contrast Injected (disqualified)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" noMoreQuestions="true"/>
               <AllowedTerm codeValue="04" codeMeaning="No T2/FLAIR images (disqualified)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" noMoreQuestions="true"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F1 - Anatomic Center" itemNumber="1" authors="Justin Kirby" explanatoryText="Location of tumor geographic center (using either CET or nCET); If multiple lesions/tumor, the location of the single largest component of the tumor.  (multiple selections acceptable – choose up to two)" minCardinality="1" maxCardinality="2" shouldDisplay="true" groupLabel="" id="2.25.176207087037859470836228378719456039233" annotatorConfidence="false">
               <AllowedTerm codeValue="RID6440" codeMeaning="frontal lobe" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6476" codeMeaning="temporal lobe" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6493" codeMeaning="parietal lobe" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6502" codeMeaning="occipital lobe" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6472" codeMeaning="insula" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6677" codeMeaning="brainstem" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6815" codeMeaning="cerebellum" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6549" codeMeaning="lentiform nucleus" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6545" codeMeaning="caudate nucleus" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6578" codeMeaning="thalamus" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6915" codeMeaning="corpus callosum" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F2 - Side of Tumor Center" itemNumber="2" authors="Justin Kirby" explanatoryText="Side of lesion center irrespective of whether the tumor crosses into the contralateral hemisphere." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.232717518690915622770043036906281482401" annotatorConfidence="false">
               <AllowedTerm codeValue="G-A100" codeMeaning="Right" codingSchemeDesignator="SRT" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="G-A102" codeMeaning="Center/Bilateral" codingSchemeDesignator="SRT" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="G-A101" codeMeaning="Left" codingSchemeDesignator="SRT" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F3 - Functional Brain at Risk of Resection" itemNumber="3" authors="Justin Kirby" explanatoryText="Does any component of the CET or nCET abnormality involve eloquent brain, determined on the basis of suspicion that resection would result in a significant neurologic deficit (motor, language, vision)? Assume that the left hemisphere is dominant for language.  (multiple selections acceptable)" minCardinality="1" maxCardinality="4" shouldDisplay="true" groupLabel="" id="2.25.63383747108317542557506782710595448657" annotatorConfidence="false">
               <AllowedTerm codeValue="05" codeMeaning="No specific functional area involved" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="06" codeMeaning="Speech expressive" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="07" codeMeaning="Speech Receptive" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="08" codeMeaning="Motor" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="09" codeMeaning="Vision" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F22 - nCET tumor Crosses Midline" itemNumber="4" authors="Justin Kirby" explanatoryText="nCET tumor crosses midline is defined by any nCET tumor that extends into the contralateral hemisphere through white matter commissures usually expected at the midline (exclusive of herniated ipsilateral tissue)." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.122361456361381677712105130790092686431" annotatorConfidence="false">
               <AllowedTerm codeValue="10" codeMeaning="No nCET" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" defaultAnswer="true" nextId="2.25.44354855842637669359741888365294257264"/>
               <AllowedTerm codeValue="RID28475" codeMeaning="no" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID28474" codeMeaning="yes" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F13 - Definition of the non-enhancing margin (e.g. Grade III)" itemNumber="5" authors="Justin Kirby" explanatoryText="Using the T2WI preferably (or T2 FLAIR if no T2WI are available) assess the definition of the boundary between the nCET and normal parenchyma or CET.  Select no nCET if there is no identifiable nCET in the tumor matrix.  Do not include vasogenic edema in your assessment.  Evaluate the proportion of the tumor boundary that is well-defined or poorly-defined. If most of the outside non-enhancing (nCET) margin of the tumor is well-defined (i.e. sharply marginated) and smooth (geographic), versus if the margin is poorly-defined (fluffy or indistinct)." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.106559230524219651563830084341678542715" annotatorConfidence="false">
               <AllowedTerm codeValue="11" codeMeaning="Completely well-defined (100%)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="12" codeMeaning="Mostly well-defined (>two thirds)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="13" codeMeaning="Mixed (@ 50-50)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="14" codeMeaning="Mostly poorly-defined (> two thirds)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="15" codeMeaning="Completely ill-defined (100%)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="10" codeMeaning="No nCET" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" defaultAnswer="true"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="Cardinal Feature Assessments" itemNumber="6" authors="Justin Kirby" explanatoryText="Cardinal feature assessment. Assuming that the entire abnormality (“lesion”) may be comprised of: (1) an enhancing component (CET), (2) a non-enhancing component (nCET), (3) a necrotic component and (4) a edema component;  when assessing relative proportions of the these four features through the entire volume, provide in rank order where each would occur in relative proportion to the other cardinal features (where a response of 1 indicates that this feature comprises the majority of the tumor footprint and 4 is the minority). If the feature is not present with reasonable certainty then select None.    Non-enhancing tumor (nCET) is defined as regions of T2W intermediate hyperintensity (less than the intensity of cerebrospinal fluid or vasogenic edema, with corresponding T1W hypointensity) that are associated with mass effect and architectural distortion, including blurring of the gray-white interface. (This may be difficult to discern from vasogenic edema).  Edema should be greater in signal than nCET and somewhat lower in signal than CSF on T2W or T2W FLAIR. Pseudopods are characteristic of edema extending up to the subcortical white matter but not infiltrating gray matter/cortex.  Necrosis is defined as a region within the tumor that does not enhance, is intermediate to hyperintense on T2WI and hypointense on T1W images, and has an irregular border). " minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.44354855842637669359741888365294257264" annotatorConfidence="false">
               <AllowedTerm codeValue="16" codeMeaning="Cardinal Features" codingSchemeDesignator="caDSR" codingSchemeVersion="1.0" defaultAnswer="true">
                  <CharacteristicQuantification name="F6 - Relative Proportion of nCET" annotatorConfidence="false" characteristicQuantificationIndex="0">
                     <Scale scaleType="Ordinal">
                        <ScaleLevel value="1"/>
                        <ScaleLevel value="2"/>
                        <ScaleLevel value="3"/>
                        <ScaleLevel value="4"/>
                        <ScaleLevel value="None"/>
                     </Scale>
                  </CharacteristicQuantification>
                  <CharacteristicQuantification name="F14 - Relative Proportion of Edema" annotatorConfidence="false" characteristicQuantificationIndex="1">
                     <Scale scaleType="Ordinal">
                        <ScaleLevel value="1"/>
                        <ScaleLevel value="2"/>
                        <ScaleLevel value="3"/>
                        <ScaleLevel value="4"/>
                        <ScaleLevel value="None"/>
                     </Scale>
                  </CharacteristicQuantification>
                  <CharacteristicQuantification name="F5 - Relative Proportion of Enhancing Tissue" annotatorConfidence="false" characteristicQuantificationIndex="2">
                     <Scale scaleType="Ordinal">
                        <ScaleLevel value="1"/>
                        <ScaleLevel value="2"/>
                        <ScaleLevel value="3"/>
                        <ScaleLevel value="4"/>
                        <ScaleLevel value="None" nextId="2.25.26682643709598967654598600492845350904"/>
                     </Scale>
                  </CharacteristicQuantification>
                  <CharacteristicQuantification name="F7 - Relative Proportion of Necrotic Tissue " annotatorConfidence="false" characteristicQuantificationIndex="3">
                     <Scale scaleType="Ordinal">
                        <ScaleLevel value="1"/>
                        <ScaleLevel value="2"/>
                        <ScaleLevel value="3"/>
                        <ScaleLevel value="4"/>
                        <ScaleLevel value="None"/>
                     </Scale>
                  </CharacteristicQuantification>
               </AllowedTerm>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F4 - Enhancement Quality" itemNumber="7" authors="Justin Kirby" explanatoryText="Qualitative degree of contrast enhancement is defined as havingall or portions of the tumor that demonstrate significantly higher signal on the postcontrast T1W images compared to precontrast T1W images.  Mild = when barely discernible but unequivocal degree of enhancement is present relative to pre-contrast images. Marked = obvious tissue enhancement.   (If it does not appear that contrast was administered, select No Contrast Injected.)  " minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.183360277954448684227779109363922125763" annotatorConfidence="false">
               <AllowedTerm codeValue="16" codeMeaning="No Contrast Enhancement" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="RID5671" codeMeaning="Mild" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID34299" codeMeaning="Marked" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F11 - Thickness of Enhancing Margin" itemNumber="8" authors="Justin Kirby" explanatoryText="If most of the enhancing rim is thin, regular, and measures &lt; 3mm in thickness and has homogenous enhancement the grade is minimal. If most of the rim demonstrates nodular and/or thick enhancement measuring 3mm or more, the grade is thick/nodular. If there is only solid enhancement and no rim, the grade is solid.  (If it does not appear that contrast was administered, select No Contrast Injected.)" minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.107001996721789954075761163370350439566" annotatorConfidence="false">
               <AllowedTerm codeValue="16" codeMeaning="No Contrast Enhancement" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="RID5670" codeMeaning="Minimal" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID28672" codeMeaning="Thick/nodular (=> 3mm)" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID5741" codeMeaning="Solid" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F12 - Definition of the Enhancing Margin" itemNumber="9" authors="Justin Kirby" explanatoryText="Assess if most of the outside margin of the enhancement is well defined (i.e. sharply marginated) or poorly-defined (fluffy or indistinct). Are you able to easily trace the margin of enhancement? Assess the proportion of the enhancing rim that is well-defined versus poorly defined and respond accordingly. If both thicker slices and thinner slices of post-contrast images are available, use the thinner slices." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.96907076645142593218277802103517844235" annotatorConfidence="false">
               <AllowedTerm codeValue="16" codeMeaning="No Contrast Enhancement" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="17" codeMeaning="Completely well-defined (100%)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="18" codeMeaning="Mostly well-defined (> two thirds)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="19" codeMeaning="Mixed (@ 50-50)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="20" codeMeaning="Mostly poorly-defined (> two thirds)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="21" codeMeaning="Completely ill-defined (100%)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F23 - Enhancing tumor Crosses Midline" itemNumber="10" authors="Justin Kirby" explanatoryText="Enhancing tissue crosses midline is defined by any CET that extends into the contralateral hemisphere through white matter commissures usually expected at the midline (exclusive of herniated ipsilateral tissue)." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.200903160931839215990776770240425301421" annotatorConfidence="false">
               <AllowedTerm codeValue="16" codeMeaning="No Contrast Enhancement" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="RID28475" codeMeaning="no" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID28474" codeMeaning="yes" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F31 - Heterogeneity" itemNumber="11" authors="Justin Kirby" explanatoryText="When assessing the complexity of the internal architecture of the tumor on FLAIR or T2WI overall grade the uniformity of the tumor matrix (exclusive of what appears to clearly be edema).  Select completely homogeneous when the tumor matrix is completely uniform in consistency; mostly homogeneous when more than 2/3 of the tumor matrix is uniform; mixed when about half of the tumor is homogeneous; mostly heterogeneous when more than half of the tumor volume is non-uniform; completely heterogeneous when all of the tumor matrix is non-uniform.  FLAIR should be used primarily.  T2WI can be used when FLAIR images are not included." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.26682643709598967654598600492845350904" annotatorConfidence="false">
               <AllowedTerm codeValue="22" codeMeaning="Completely homogeneous (100%)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="23" codeMeaning="Mostly homogeneous (> two thirds)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="24" codeMeaning="Mixed (@ 50-50)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="25" codeMeaning="Mostly heterogeneous (> two thirds)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="26" codeMeaning="Completely heterogeneous (100%)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="27" codeMeaning="Indeterminate" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" defaultAnswer="true"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F32 - Shape" itemNumber="12" authors="Justin Kirby" explanatoryText="Shape is defined as the overall contour of the abnormal tissue that you would characterize as a tumor boundary. Which descriptor best defines the shape of the entire mass: round, ovoid, lobulated or irregular.  Consider the overall boundaries of the CET primarily.  If there is no CET, then consider the shape of the nCET exclusive of edema.  If neither seem to apply, select none apply." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.89697414760266572521897673992093043420" annotatorConfidence="false">
               <AllowedTerm codeValue="RID29173" codeMeaning="Round/Circular/Spherical" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID29223" codeMeaning="Ovoid" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID29174" codeMeaning="Lobulated" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID29215" codeMeaning="Irregular" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID28454" codeMeaning="None Apply" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F8 - Cyst(s)" itemNumber="13" authors="Justin Kirby" explanatoryText="Cysts are well defined, rounded, often eccentric regions of very bright T2W signal and low T1W signal essentially matching CSF signal intensity, with very thin, regular, smooth, nonenhancing or regularly enhancing walls, possibly with thin, regular, internal septations.  Differentiate from a necrotic enhancing tumor cavity with thick irregular walls and complex internal fluid." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.36798094312158401784401963599403502954" annotatorConfidence="false">
               <AllowedTerm codeValue="RID28473" codeMeaning="absent" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="RID28472" codeMeaning="present" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F24 - Satellites" itemNumber="14" authors="Justin Kirby" explanatoryText="A satellite lesion is defined by one or more areas of nCET or CET within the region of signal abnormality surrounding the dominant lesion but not contiguous in any part with the major tumor mass.  This is in distinction from a multifocal lesion." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.250254746072336007090635407167613459133" annotatorConfidence="false">
               <AllowedTerm codeValue="RID28473" codeMeaning="absent" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="RID28472" codeMeaning="present" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F9 - Multifocal or Multicentric" itemNumber="15" authors="Justin Kirby" explanatoryText="Multifocal is defined as having at least one region of abnormal tissue, either enhancing or nonenhancing, which is not contiguous with the dominant lesion and is outside the region of signal abnormality (edema) surrounding the dominant mass. This can be defined as those resulting from dissemination or growth by an established route, spread via commissural or other pathways, or via CSF channels or local metastases, whereas Multicentric are widely separated lesions in different lobes or different hemispheres that cannot be attributed to one of the previously mentioned pathways. Gliomatosis refers to generalized neoplastic transformation of the white matter of most of a hemisphere." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.122848646282931218782733302616118513507" annotatorConfidence="false">
               <AllowedTerm codeValue="RID5702" codeMeaning="Focal" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID5703" codeMeaning="Multifocal or Multicentric" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="28" codeMeaning="Gliomatosis Cerebri" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F10 - T1/FLAIR Ratio" itemNumber="16" authors="Justin Kirby" explanatoryText="T1/FLAIR ratio is a gross comparison in the overall lesion size between pre-contrast T1 and FLAIR (in the same plane).  Select T1~FLAIR when pre-contrast T1 abnormality (exclusive of signal intensity) approximates size of FLAIR abnormality; Select T1&lt;FLAIR when the size of T1 abnormality is moderately smaller than the surrounding FLAIR envelope;  or select T1&lt;&lt;FLAIR when the size of the pre-contrast T1 abnormality is much smaller than size of FLAIR abnormality. (If no FLAIR images were provided select No FLAIR images)." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.192557928867048244599609691480357185195" annotatorConfidence="false">
               <AllowedTerm codeValue="29" codeMeaning="T1 ~ FLAIR" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="30" codeMeaning="T1 &lt; FLAIR" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="31" codeMeaning="T1 &lt;&lt; FLAIR" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F16 - Hemorrhage" itemNumber="17" authors="Justin Kirby" explanatoryText="Intrinsic hemorrhage anywhere in the tumor matrix. Any intrinsic foci of low signal on T2WI (or gradient echo) or high signal on T1WI.  Proportion is not a discriminating factor. Select cannot determine if findings are indistinct or may actually represent mineral instead of hemorrhage." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.244477578050994548304476816368493665785" annotatorConfidence="false">
               <AllowedTerm codeValue="RID28475" codeMeaning="no" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID28474" codeMeaning="yes" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="27" codeMeaning="Indeterminate" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0" defaultAnswer="true"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F17 - Diffusion" itemNumber="18" authors="Justin Kirby" explanatoryText="Proportion of CET and nCET demonstrating ADC below or same as the ADC of normal-appearing brain. The remainder of the abnormality is assumed to demonstrate increased ADC relative to normal brain. (Based on ADC map only). Select equivocal when findings are equivocal.   (Select no ADC images if ADC images were not provided)" minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.195794272294395372341575500719340322354" annotatorConfidence="false">
               <AllowedTerm codeValue="C48660" codeMeaning="No ADC images" codingSchemeDesignator="NCIt" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="32" codeMeaning="> 2/3" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="33" codeMeaning="1/3 - 2/3" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="34" codeMeaning="&lt; 1/3" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="35" codeMeaning="Minimal (&lt;5%)" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID28454" codeMeaning="None" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="36" codeMeaning="Equivocal" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F18 - Leptomeningeal reaction" itemNumber="19" authors="Justin Kirby" explanatoryText="Leptomeningeal reaction is defined by enhancement of the overlying pia/arachnoid in continuity with enhancing or non-enhancing tumor or sulcal hyperintensity on T2 FLAIR. This should be selected to capture reactive leptomeninges and/or invaded leptomeninges." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.108391085698639462771043090863419726717" annotatorConfidence="false">
               <AllowedTerm codeValue="RID28473" codeMeaning="absent" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="RID28472" codeMeaning="present" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F19 - Ependymal contact" itemNumber="20" authors="Justin Kirby" explanatoryText="Ependymal contact is defined by tumor abutting any adjacent ependymal surface in continuity with enhancing or non-enhancing tumor matrix.  If there is CET in contact with the ependyma, select enhancing. If there is nCET in contact with the ependyma, select non-enhancing.  If nCET and CET are in contact with the ependymal, select both. Enhancement of the ependyma is not necessary if abutted by nCET; if abutted by CET, ependymal enhancement is necessary." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.139645378053990855460137174034728343184" annotatorConfidence="false">
               <AllowedTerm codeValue="RID28473" codeMeaning="absent" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="RID6055" codeMeaning="enhancing" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6056" codeMeaning="nonenhancing" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="37" codeMeaning="Both" codingSchemeDesignator="99VASARI" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F20 - Cortical involvement" itemNumber="21" authors="Justin Kirby" explanatoryText="Using T2 FLAIR preferably (or T2WI if T2 FLAIR are not available). Cortical involvement is defined by non-enhancing or enhancing tumor that extends into the cortical mantle, or if the cortex is no longer distinguishable relative to tumor." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.167777512011251856249859492928947268475" annotatorConfidence="false">
               <AllowedTerm codeValue="RID28473" codeMeaning="absent" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="RID28472" codeMeaning="present" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F21 - Deep WM Invasion" itemNumber="22" authors="Justin Kirby" explanatoryText="Deep white matter invasion is defined by enhancing or nCET tumor extending into the internal capsule, corpus callosum or brainstem. (multiple choices allowed)" minCardinality="1" maxCardinality="3" shouldDisplay="true" groupLabel="" id="2.25.158474128294561234684698963176949745267" annotatorConfidence="false">
               <AllowedTerm codeValue="RID28454" codeMeaning="none" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="RID6915" codeMeaning="corpus callosum" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6941" codeMeaning="internal capsule" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
               <AllowedTerm codeValue="RID6677" codeMeaning="brainstem" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
            <ImagingObservationCharacteristic label="F25 - Calvarial remodeling" itemNumber="23" authors="Justin Kirby" explanatoryText="Calvarial remodeling is defined as visible erosion/remodeling of inner table of skull (possibly a secondary sign of slow growth)." minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.232585054265451406016857784730316000640" annotatorConfidence="false">
               <AllowedTerm codeValue="RID28473" codeMeaning="absent" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
               <AllowedTerm codeValue="RID28472" codeMeaning="present" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0"/>
            </ImagingObservationCharacteristic>
         </ImagingObservation>
         <AllowedTerm codeValue="RID4026" codeMeaning="glioma" codingSchemeDesignator="RadLex" codingSchemeVersion="1.0" defaultAnswer="true"/>
      </Component>
      <Component label="Lesion Size: Longest Diameter - Lesion size is defined as the largest perpendicular (x-y) cross- sectional diameter of entire T2 or FLAIR signal abnormality (longest dimension x perpendicular dimension) measured the single axial image that reveals the largest cross-sectional area of the lesion. Measurement should incorporate all cardinal imaging features of CET, nCET, necrosis and edema. (Measurement lines may cross cystic or necrotic components of the signal abnormality but should not cross through the ventricles)." itemNumber="1" authors="Justin Kirby" explanatoryText="" minCardinality="1" maxCardinality="1" shouldDisplay="true" groupLabel="" id="2.25.314331443843585035410609477037874999702">
         <GeometricShape>MultiPoint</GeometricShape>
      </Component>
      <Component label="Lesion Size: Longest Perpendicular - Lesion size is defined as the largest perpendicular (x-y) cross- sectional diameter of entire T2 or FLAIR signal abnormality (longest dimension x perpendicular dimension) measured the single axial image that reveals the largest cross-sectional area of the lesion. Measurement should incorporate all cardinal imaging features of CET, nCET, necrosis and edema. (Measurement lines may cross cystic or necrotic components of the signal abnormality but should not cross through the ventricles)." itemNumber="2" authors="Default User" explanatoryText="" minCardinality="1" maxCardinality="1" shouldDisplay="false" groupLabel="" id="2.25.172261015044643220638473649057008890583">
         <GeometricShape>MultiPoint</GeometricShape>
      </Component>
   </Template>
</TemplateContainer>